Andere Sprachen Stayble Therapeutics AB

Aktien

A2P1F3

SE0013513652

STABL

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 15:53:18 28.05.2024			% 5 Tage	% 1. Jan.
0.24 ^SEK	-2.24%		-1.44%	-20.79%

21.05.	Stayble Therapeutics AB (publ) meldet Ergebnis für das erste Quartal zum 31. März 2024	CI
20.02.	Stayble Therapeutics AB (publ) meldet Ergebnis für das vierte Quartal und das Gesamtjahr zum 31. Dezember 2023	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Stayble Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	21.05.
Stayble Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	20.02.
Stayble's CEO to BioStock: "We are looking forward to new study results in 2024"	12.01.
BioStock: Stayble's new analyses of phase IIb study strengthen disc herniation project	18.12.
Stayble Therapeutics Announces New Analyses of Phase IIb Study Strengthen Disc Herniation Project	18.12.
BioStock: Stayble Therapeutics shifts focus to phase Ib study in disc herniation	22.11.
Stayble Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14.11.
BioStock: Stayble did not reach the primary endpoint in phase IIb	09.11.
BioStock: Stayble Therapeutics presents phase IIb data within one month	03.11.
Toleranzia Appoints Successor to Outgoing CFO	16.10.23
BioStock: Stayble reports last patient last visit in the phase IIb study	14.09.23
Stayble Therapeutics Terminates Liquidity Provider Agreement	06.09.23
BioStock: Stayble enrols the first patient in herniated disc study	04.09.23
Stayble Enters the First Patient in Herniated Disc Study	04.09.23
Stayable Therapeutics Enrols First Patient for Herniated Discs Trial	28.08.23
BioStock: Progress for Stayble Therapeutics in the second quarter	25.08.23
Stayble Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	22.08.23
Certain Shares of Stayble Therapeutics AB are subject to a Lock-Up Agreement Ending on 22-AUG-2023.	22.08.23
BioStock: Stayble's phase IIb study nears the finishing line	24.07.23
Stayble Therapeutics Phase IIb Study Nears the Final Line	24.07.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Stayble Therapeutics AB

Aktien

A2P1F3

SE0013513652

STABL

Andere Sprachen

Filter